Trial Profile

Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Overweight or Obesity, and Knee Osteoarthritis (AMAZE 5)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 26 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zenagamtide (Primary)
Indications Obesity; Osteoarthritis
Focus Registrational; Therapeutic Use
Acronyms AMAZE 5; AMAZE-5
Sponsors Novo Nordisk

Most Recent Events

29 Apr 2026 Planned End Date changed from 17 Jul 2028 to 14 Aug 2028.
29 Apr 2026 Planned primary completion date changed from 19 Jun 2028 to 14 Aug 2028.
27 Apr 2026 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com